46. 悪性関節リウマチ
[臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219

Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
13 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02236481
(ClinicalTrials.gov)
July 20138/9/2014Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and DiabetesNo-profit Study to Ensure Normal Clinical Practice, to Evaluate the Efficacy of Anakinra in Reducing the Glycated Haemoglobin in Patients Affected by Rheumatoid Arthritis and Diabetes; Randomized, Open Label, Parallel Group,Controlled Clinical StudyDiabetes Mellitus, Type 2;Arthritis, RheumatoidDrug: Anakinra;Drug: TNF alpha inhibitorsProf. Roberto GiacomelliNULLTerminated18 YearsN/AAll41Phase 4Italy
2EUCTR2012-005370-62-IT
(EUCTR)
18/02/201311/01/2013clinical study to evaluate the efficacy of anakinra in reducing the glycated haemoglobin in patients affected by rheumatoid arthritis and diabetes.No-profit” clinical study for the improvement of clinical practice, to evaluate the efficacy of anakinra in reducing the glycated haemoglobin in patients affected by rheumatoid arthritis and diabetes; randomized, open label, parallel group, controlled clinical study. rheumatoid arthritis and type 2 diabetes mellitus as comorbidity.
MedDRA version: 14.1;Level: LLT;Classification code 10037740;Term: RA;System Organ Class: 100000004859
MedDRA version: 14.1;Level: PT;Classification code 10012601;Term: Diabetes mellitus;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: KINERET*SC 7SIR 100MG 0,67ML
INN or Proposed INN: ANAKINRA
OSPEDALE CIVILE SAN SALVATORE, ASL 04, L'AQUILANULLNot RecruitingFemale: yes
Male: yes
200Phase 4Italy
3NCT02915094
(ClinicalTrials.gov)
October 201223/9/2016Kineret in the Treatment of Rheumatoid ArthritisKineret in the Treatment of Rheumatoid ArthritisRheumatoid ArthritisDrug: AnakinraSwedish Orphan BiovitrumNULLCompleted18 YearsN/AAll30N/AGermany
4NCT01566201
(ClinicalTrials.gov)
March 201127/3/2012Effects of Interleukin-1 Inhibition on Vascular and Left Ventricular Function in Rheumatoid Arthritis Patients With Coronary Artery DiseaseThe Effect of Inhibition of Interleukin-1 Activity on Vascular and Left Ventricular Function in Patients With Coronary Artery Disease and Coexistent Rheumatoid ArthritisRheumatoid Arthritis;Coronary Artery Disease;InflammationDrug: anakinra;Drug: placeboUniversity of AthensNULLCompleted18 YearsN/ABoth80N/AGreece
5ChiCTR-TRC-09000383
2008-01-012009-04-23Efficacy and safety of recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis: a double-blind, randomized, placebo-controlled trialEfficacy and safety of recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial rheumatoid arthritis;M05.901placebo:daily subcutaneous injections of placebo, with concurrent MTX therapy ;anakinra:daily subcutaneous injections of anakinra (80 mg), with concurrent MTX therapy;Xi-jing Hospital, the 4th Military Medical University, Shanghai Changzheng HospitalNULLCompleted1865Bothplacebo:10;anakinra:30;3 (Phase 3 study)China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00111410
(ClinicalTrials.gov)
August 200520/5/2005Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)A Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Estimate the Effect of Anakinra (r-metHuIL-1ra) on Vaccine Antibody Response in Subjects With Rheumatoid Arthritis (RA)Rheumatoid ArthritisDrug: Anakinra (r-metHuIL-1ra)AmgenNULLCompleted18 Years74 YearsBothPhase 4NULL
7NCT00117091
(ClinicalTrials.gov)
September 200430/6/2005Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)An Open-Label Multicentre Study of Anakinra (Kineret®) in Combination With DMARDS in Subjects With Active Rheumatoid Arthritis (RA)Rheumatoid ArthritisDrug: Anakinra (Kineret®)AmgenNULLCompleted18 YearsN/ABothPhase 3NULL
8NCT00213538
(ClinicalTrials.gov)
June 200313/9/2005Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid ArthritisGene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid ArthritisRheumatoid ArthritisDrug: Response to anakinra associated with methotrexateUniversity Hospital, RouenNULLCompleted18 YearsN/AAll341N/AFrance
9NCT00121043
(ClinicalTrials.gov)
October 200230/6/2005Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported QuestionnaireAn Open Label, Randomized, Crossover Study to Assess Acceptability and Functionality of SimpleJectTM Vs Pre-Filled Syringe(s) Using Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using A Self-Reported QuestionnaireRheumatoid ArthritisDevice: SimpleJectTM;Drug: Kineret® (Anakinra)AmgenNULLCompleted18 YearsN/ABothPhase 4NULL
10NCT00537667
(ClinicalTrials.gov)
August 200127/9/2007The SPECTRA StudyA Single Centre, Open-Label, Randomised, Study to Evaluate the Effect of Anakinra (r-metHuIL-1ra) Alone and in Combination With PEGylated Recombinant Methionyl Human Soluble Tumour Necrosis Factor Receptor Type I (PEG sTNF-RI) on Synovial Inflammation in Subjects With Rheumatoid Arthritis.Rheumatoid ArthritisDrug: anakinra;Drug: anakinra and PEG sTNF-R1AmgenNULLTerminated18 YearsN/ABoth22Phase 2NULL
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00037700
(ClinicalTrials.gov)
May 200120/5/2002Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid ArthritisRheumatoid ArthritisDrug: anakinra;Drug: pegsunerceptAmgenNULLCompleted18 YearsN/ABothPhase 2United States
12NCT00037648
(ClinicalTrials.gov)
July 200017/5/2002Juvenile Rheumatoid ArthritisA Randomized, Multi-center, Blinded, Placebo-controlled Study With an Open-label Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHuIL-1ra (Anakinra) in Polyarticular-Course Juvenile Rheumatoid ArthritisJuvenile Chronic ArthritisDrug: Anakinra;Drug: PlaceboAmgenNULLCompleted2 Years17 YearsBoth86Phase 2United States
13EUCTR2015-002466-22-Outside-EU/EEA
(EUCTR)
23/12/2015A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Openlabel Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHuiL-1ra (Anakinra) in Polyarticular-Course Juvenile Rheumatoid ArthritisA Randomized, Multi-center, Blinded, Placebo-controlled Study With an Open­label Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHuiL-1ra (Anakinra) in Polyarticular-Course Juvenile Rheumatoid Arthritis Juvenile Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Name: anakinra
INN or Proposed INN: ANAKINRA
Amgen IncNULLNAFemale: yes
Male: yes
90United States;Australia;Canada;Costa Rica;New Zealand